-
公开(公告)号：US09212173B2
公开(公告)日：2015-12-15
申请号：US14531271
申请日：2014-11-03
Applicant: Genentech, Inc.
Inventor： Charles Baker-Glenn , Daniel Jon Burdick , Bryan K. Chan , Mark Chambers , Huifen Chen , Anthony Estrada , Zachary Kevin Sweeney
IPC: A61K31/506 , C07D403/12 , C07D413/14 , C07D403/14 , C07D407/14 , C07D405/14
CPC classification number: C07D403/12 , A61K31/506 , C07D403/14 , C07D405/14 , C07D407/14 , C07D413/14
Abstract: Pyrazole compounds that are modulators of LRRK2, methods of making the compounds, and methods for using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
Abstract translation: 作为LRRK2的调节剂的吡唑化合物，制备化合物的方法，以及使用该化合物治疗与LRRK2受体相关的疾病如帕金森病的方法。
-
公开(公告)号：US20150328195A1
公开(公告)日：2015-11-19
申请号：US14743835
申请日：2015-06-18
Applicant: GENENTECH, INC.
Inventor： Hazel Joan Dyke , Lewis Gazzard , Karen Williams , Huifen Chen , Samuel Kintz , Joy Drobnick , Joseph P. Lyssikatos , Simon Goodacre , Calum Macleod , Charles Ellwood
IPC: A61K31/4375 , C07D471/14 , A61K31/496 , A61K45/06 , C07D453/02 , C07D519/00 , A61K31/55 , A61K31/5377 , A61K31/439
CPC classification number: C07D471/14 , A61K31/4375 , A61K31/439 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K31/55 , A61K45/06 , C07D453/02 , C07D519/00
Abstract: The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
Abstract translation: 本发明涉及可用作激酶抑制剂的式（I），（I-a）和（I-b）的1,7-二氮杂咔唑化合物，更具体地用作检查点激酶1（chk1）抑制剂，因此可用作癌症治疗剂。 本发明还涉及包含这些化合物的组合物，更具体地是包含这些化合物的药物组合物以及使用该组合物治疗各种形式的癌症和过度增殖性疾病的方法，以及将该化合物用于体外，原位和体内诊断或 治疗哺乳动物细胞或相关病理状况。
-
公开(公告)号：US20150218176A1
公开(公告)日：2015-08-06
申请号：US14688724
申请日：2015-04-16
Applicant: Genentech, Inc.
Inventor： Daniel Burdick , Huifen Chen , Shumei Wang , Weiru Wang
IPC: C07D487/04 , A61K45/06 , A61K31/4985
CPC classification number: C07D487/04 , A61K31/4985 , A61K45/06
Abstract: Compounds having the formula I wherein R1 and R2 are as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.
Abstract translation: 具有式I的化合物，其中R 1和R 2如本文所定义，是ERK激酶的抑制剂。 还公开了用于治疗过度增殖性疾病的组合物和方法。
-
公开(公告)号：US20150051238A1
公开(公告)日：2015-02-19
申请号：US14531271
申请日：2014-11-03
Applicant: Genentech, Inc.
Inventor： Charles Baker-Glenn , Daniel Jon Burdick , Bryan K. Chan , Mark Chambers , Huifen Chen , Anthony Estrada , Zachary Kevin Sweeney
IPC: C07D403/12 , C07D405/14 , C07D413/14 , C07D403/14
CPC classification number: C07D403/12 , A61K31/506 , C07D403/14 , C07D405/14 , C07D407/14 , C07D413/14
Abstract: Pyrazole compounds that are modulators of LRRK2, methods of making the compounds, and methods for using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
Abstract translation: 作为LRRK2的调节剂的吡唑化合物，制备化合物的方法，以及使用该化合物治疗与LRRK2受体相关的疾病如帕金森病的方法。
-
公开(公告)号：US08802674B2
公开(公告)日：2014-08-12
申请号：US13712015
申请日：2012-12-12
Applicant: Genentech, Inc.
Inventor： Charles Baker-Glenn , Daniel Jon Burdick , Mark Chambers , Bryan K. Chan , Huifen Chen , Anthony Estrada , Janet Gunzner-Tate , Daniel Shore , Zachary Kevin Sweeney , Shumei Wang , Guiling Zhao
IPC: A61K31/535 , C07D413/14 , C07D498/06 , C07D473/16 , C07D403/14 , C07D413/12
CPC classification number: C07D413/14 , C07D403/14 , C07D413/12 , C07D473/16 , C07D498/06 , C07D498/08
Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n. X, R1, R2, R3, R5, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
Abstract translation: 式I化合物或其药学上可接受的盐，其中m，n。 X，R 1，R 2，R 3，R 5，R 6和R 7如本文所定义。 还公开了制备化合物和使用该化合物治疗与LRRK2受体（例如帕金森病）相关的疾病的方法。
-
Patent Agency Ranking
公开(公告)号：US12202824B2
公开(公告)日：2025-01-21
申请号：US17816855
申请日：2022-08-02
Applicant: Genentech, Inc.
Inventor： Jack Alexander Terrett , Huifen Chen , Lea Constantineau-Forget , Robin Larouche-Gauthier , Luce Lépissier , Francis Beaumier , Martin Déry , Chantal Grand-Maître , Claudio Sturino , Matthew Volgraf , Elisia Villemure
IPC: C07D413/14 , A61K31/427 , A61K31/437 , A61K31/4375 , A61K31/4985 , A61K31/5025 , A61K31/519 , A61K31/522 , A61K31/53 , A61P11/00 , A61P19/02 , A61P23/00 , A61P25/00 , A61P29/00 , C07D471/04 , C07D473/08 , C07D473/30 , C07D487/04 , C07D498/04 , C07D513/04
Abstract: The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof wherein A, X, R1, R4 and n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
-
公开(公告)号：US20230002391A1
公开(公告)日：2023-01-05
申请号：US17340082
申请日：2021-06-06
Applicant: Genentech, Inc.
Inventor： Snahel Patel , Gregory Hamilton , Craig Stivala , Huifen Chen , Blake Daniels
IPC: C07D487/04 , C07D231/54 , C07D249/16 , A61P25/00
Abstract: The invention provides novel compounds having the general formula I: wherein R1, RB1, RB2, n, p, q, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.
-
公开(公告)号：US11072617B2
公开(公告)日：2021-07-27
申请号：US16175206
申请日：2018-10-30
Applicant: Genentech, Inc.
Inventor： Snahel Patel , Gregory Hamilton , Craig Stivala , Huifen Chen , Blake Daniels
IPC: C07D487/04 , C07D231/54 , C07D249/16 , A61P25/00
Abstract: The invention provides novel compounds having the general formula I: wherein R1, RB1, RB2, n, p, q, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.
-
公开(公告)号：US20190300521A1
公开(公告)日：2019-10-03
申请号：US16372345
申请日：2019-04-01
Applicant: Arvinas Operations, Inc. , Genentech, Inc.
Inventor： Andrew P. Crew , Jing Wang , Michael Berlin , Peter Dragovich , Huifen Chen , Leanna Staben
Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
-
公开(公告)号：US09963446B2
公开(公告)日：2018-05-08
申请号：US15266243
申请日：2016-09-15
Applicant: Genentech, Inc.
Inventor： Jason Burch , Huifen Chen , Xiaojing Wang
IPC: C07D417/14 , A61K31/427 , A61K31/4439 , A61K31/4709 , A61K31/497 , A61K31/4985 , A61K31/06 , C07D487/04 , A61K45/06
CPC classification number: C07D417/14 , A61K31/427 , A61K31/4439 , A61K31/4709 , A61K31/497 , A61K31/4985 , A61K45/06 , C07D487/04
Abstract: Oxepan-2-yl pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
-
-
-
-
-
-
-
-
-
Search Results
71
records
(took 0.071 seconds)
